135.83
前日終値:
$132.83
開ける:
$133.62
24時間の取引高:
124.87K
Relative Volume:
0.89
時価総額:
$2.62B
収益:
$152.42M
当期純損益:
$45.24M
株価収益率:
54.12
EPS:
2.51
ネットキャッシュフロー:
$6.97M
1週間 パフォーマンス:
-2.35%
1か月 パフォーマンス:
+17.38%
6か月 パフォーマンス:
+18.08%
1年 パフォーマンス:
+28.13%
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
名前
Ligand Pharmaceuticals Inc
セクター
電話
858-550-7500
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
LGND
Ligand Pharmaceuticals Inc
|
135.83 | 2.56B | 152.42M | 45.24M | 6.97M | 2.51 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-10 | 開始されました | Stifel | Buy |
2024-10-03 | 開始されました | Oppenheimer | Outperform |
2024-07-30 | 開始されました | RBC Capital Mkts | Outperform |
2021-04-14 | 再開されました | Stephens | Overweight |
2021-02-04 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-06 | 開始されました | Barclays | Overweight |
2020-03-24 | ダウングレード | Argus | Buy → Hold |
2020-03-10 | 開始されました | Guggenheim | Neutral |
2020-02-06 | 開始されました | The Benchmark Company | Buy |
2019-09-19 | アップグレード | Barclays | Equal Weight → Overweight |
2019-06-11 | 開始されました | Barclays | Equal Weight |
2019-05-03 | 繰り返されました | H.C. Wainwright | Buy |
2019-03-06 | 繰り返されました | H.C. Wainwright | Buy |
2018-10-29 | アップグレード | ROTH Capital | Neutral → Buy |
2018-10-02 | 繰り返されました | H.C. Wainwright | Buy |
2018-09-11 | 繰り返されました | Argus | Buy |
2018-08-17 | 開始されました | Goldman | Neutral |
2018-08-08 | ダウングレード | ROTH Capital | Buy → Neutral |
2018-06-21 | 開始されました | Argus | Buy |
2017-12-27 | 繰り返されました | H.C. Wainwright | Buy |
2017-09-05 | 再開されました | H.C. Wainwright | Buy |
2016-10-05 | 繰り返されました | H.C. Wainwright | Buy |
2016-08-05 | ダウングレード | Deutsche Bank | Hold → Sell |
2016-03-11 | 開始されました | Sidoti | Buy |
2016-03-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-margin investment plays - PrintWeekIndia
What drives Ligand Pharmaceuticals Incorporated stock priceBreakout portfolio performance - Autocar Professional
Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan
What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional
Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated stock a growth or value playFree Capital Allocation Plans - beatles.ru
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛
Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia
Ligand Pharmaceuticals Director John Kozarich Sells 934 Shares at $125/Share. - AInvest
Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest
Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits
ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest
ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest
Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener
Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener
Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire
Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan
GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World
Ligand’s LNHC concludes merger with CHRO - Yahoo Finance
Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times
Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals - Quiver Quantitative
Ligand completes merger, Pelthos to launch molluscum treatment - Investing.com
Ligand Pharmaceuticals Inc (LGND) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):